ACC 2019

ACC 2019 | STOPDAPT-2: P2Y12 Monotherapy After Short-Term Dual Antiplatelet Therapy After Angioplasty

Aspirin is against the ropes: first, it was primary prevention; now, its use is being reconsidered even...

ACC 2019 | SMART-CHOICE: Aspirin Increasingly “Against the Ropes”

This work (presented during the same American College of Cardiology 2019 Scientific Session as the STOPDAPT-2...

ACC 2019 | AUGUSTUS: Apixaban Plus P2Y12 Inhibitor Is the Best Combination in Atrial Fibrillation and Angioplasty

Aspirin increases bleeding with no ischemic benefit, but a trend toward more stent thrombosis with placebo warrants...

ACC 2019 | The New ACC/AHA Guidelines on Primary Prevention Focus on Life Style, Diet and Socioeconomic Factors.

These guidelines basically remind us that we should focus on life style changes to best prevent heart...

ACC 2019 | TAVR in Bicuspids is Safe and Feasible in Real World Patients

Experts still won’t agree on whether to carry out randomized trial to put an end to this...

ACC 2019 | POET: Oral Antibiotics with Good Long-Term Results for Endocarditis

This work found better survival rates with oral treatment, an outcome that may be credited to shorter...

ACC 2019 | Having an Infarction at Very Young Age or 10 Years Later Does Not Change Long-Term Mortality

Patients who suffered their first coronary event before turning 40 years old have similar long-term mortality to those...

ACC 2019 | SAFARI: Unexpectedly, Radial Approach Offers No Benefits In STEMI

This study was not able to show benefits in terms of mortality or bleeding when using radial...